What S2283 Actually Does — and Why It Is a Research Pilot, Not Legalization
In January 2026, the New Jersey Legislature passed Senate Bill S2283, formally titled the Psilocybin Behavioral Health Access and Services Act. On January 20, 2026, shortly before leaving office, Governor Phil Murphy signed the bill into law.
Despite widespread media coverage suggesting that New Jersey has “legalized psilocybin,” S2283 does not create legal public access to psilocybin. Instead, it establishes a narrow, state-run, hospital-based research pilot designed to study the clinical use of psilocybin under tightly controlled medical conditions.
What the Bill Does
At its core, S2283 creates a Psilocybin Behavioral Health Access and Therapy Pilot Program under the authority of the New Jersey Department of Health. The purpose of the program is explicitly evaluative: to generate clinical outcome data and assess whether psilocybin therapy should play a role in New Jersey’s future mental health care system.
